Cipla (CIPL.BO): Opening 90D +ve CW: US Triggers, Valuation Comfort, Strong India Play

Research evidence excerpt

Cipla (CIPL.BO): Opening 90D +ve CW: US Triggers, Valuation Comfort, Strong India Play

Cipla (CIPL.BO)

20 June 2026 Citi Research

Pipeline catalysts in near term; Indore clearance can help in scale and cost – PAI inspection of Cipla’s Goa facility paves the

way for approval of a key inhaler asset, likely generic Flovent HFA (110 mcg; c.US$200m brand). Near-term catalysts include the

launch of Ventolin HFA (already approved) and expected Advair approval, while Symbicort and a peptide asset (likely

Teduglutide) remain key 2HFY27 approval candidates. We estimate a cumulative annual sales opportunity of US$270m–

500m (Fig: 3) from these assets, subject to the company’s market share in these products. Additionally, Cipla’s strong ~50%

share in Nintedanib should support QoQ growth in US revenues in 1QFY27. The Indore facility re-inspection is due anytime, and

a USFDA clearance would provide another near-term catalyst; while approvals are largely de-risked, such clearance would

enable meaningful scale-up and cost efficiencies.

India business tracking well in 1QFY27E – The company has guided for double-digit India growth in FY27E, with the 1Q setup

appearing strong—secondary sales are tracking at ~12–14% growth in Apr–May, aided by a recovery in the respiratory segment

on a low base. Additionally, the company’s GLP-1 asset Yurpeak (partnered with Lilly) has gained traction, with ~Rs268m sales

in May month.

Valuations yet to anchor towards India Biz – Cipla is the 3rd largest player in the domestic market and has seen a recovery in

domestic growth, supported by a rebound in the respiratory segment of the IPM. The India business contributes roughly 2/3rd

of overall EBITDA, yet valuations remain anchored to generic-heavy peers rather than India-focused players like Mankind. The